NovoCure Limited (NASDAQ:NVCR) Q3 2023 Earnings Call Transcript

Page 5 of 5

Bill Doyle: So, thank you very much. I want to thank everyone for your continued interest and support in NovoCure. The messages I want you to take away from this call are, first and foremost, that we are executing our plan. GBM is a stable business that’s providing the financial support for us to invest in our future. We have made exciting clinical progress, first and foremost, in our thoracic program where we are preparing to launch around the world, and in the future, where we are excited by the imminent prospects of METIS and PANOVA-3 next year. So, it’s an exciting time to be at NovoCure. It’s a busy time. We stand with our Israeli colleagues, and we couldn’t be more appreciative of their hard work during this incredibly difficult time in that country. So, thanks again and we look forward to reporting next quarter.

Operator: This concludes today’s conference call. Thank you for participating and you may now disconnect.

Follow Novocure Ltd (NASDAQ:NVCR)

Page 5 of 5